



Acarix secures a multi-unit order from major cardiology practice with several offices in Florida

Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, has announced that the CADScor System is now available at multiple clinics within Miami's Amavita Heart and Vascular Health™, a leading cardiovascular practice.

"We take pride in our ability to offer state-of-the-art testing and diagnostics while providing value-based quality care to our patients," stated Dr. Pedro Martinez-Clark, MD, FACC, founder and interventional cardiologist. "Incorporating the CADScor System into the diagnostic toolbox allows us to provide patients with suspected coronary artery disease a fast and easy test with results at the point of care. We acknowledge that waiting for results can be an anxiety-inducing experience for patients, so we have minimized the wait time by including the CADScor System in our diagnostic workflow. Instead of our patients waiting to receive results, they can immediately start working with our team to focus on the next steps to address their needs."

Amavita Heart and Vascular Health™ operates several locations throughout Miami-Dade County, enabling the practice to serve patients across South Florida. Their main objective is to enhance cardiovascular outcomes using advanced technology and interventions while providing empathetic care to all patients.

"We are pleased to announce the incorporation of the CADScor System within an advanced facility like Amavita Heart and Vascular Health™," commented Acarix President & CEO Aamir Mahmood. "The CADScor System represents a pivotal step towards value-based care in cardiology. Providing an accurate and non-invasive tool for risk stratification of coronary artery disease at the point of care empowers clinicians to tailor decisions more precisely, leading to better outcomes and cost-effective care. This technology enhances the patient experience by minimizing unnecessary procedures and aligns with the healthcare industry's shift towards value-driven practices, where quality and efficiency are paramount."

For more information contact:

Jennifer Anderson, Head of Marketing & Communications, phone +1 720 471 4625, email jennifer.anderson@acarix.com

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

13 May 2024 09:45:00 CEST



Attachments

[Acarix secures a multi-unit order from major cardiology practice with several offices in Florida](#)